Upsher -Smith the competitor for the Vigabatrin anda was bought by Bora Pharma a Taiwanese corp in January 2024 for only $210 M . Upsher launched its Vigadrone Oral Solution in 2018 and has now included Vigadrone Tablets, a branded-generic everolimus tablet, which they plan to launch soon according to a press release on April 12 announcing the expansion of its rare disease portfolio. They will be participating at the American Academy of Neurology meeting in Denver from April 13-18 2024. The Vigapoder Pyros product v Vigadrone Upsher products competition has started.
Market Data 
Markets 
AI
